Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting
News Jun 04, 2012
Axelar AB has announced the release of a poster at The American Society of Clinical Oncology (ASCO) Annual Meeting with data from the Phase I/II trial of AXL1717 that was completed in 2011.
The poster entitled “A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A Phase I clinical trial.” is available on the Axelar and Karolinska Development websites (www.axelar.se and www.karolinskadevelopment.com).
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE